Group 1 - The company Silk Road Vision (SZ 300556) held its ninth board meeting of the fifth session on October 24, 2025, via telecommunication voting, discussing the proposal for the management system for senior executives' departure [1] - For the first half of 2025, Silk Road Vision's revenue composition was 99.98% from CG business and 0.02% from other businesses [1] - As of the report date, Silk Road Vision's market capitalization was 2.5 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [1]

Group 1 - The core point of the news is that Silk Road Vision (SZ 300556) announced the completion of a share reduction plan by shareholders Ding Pengqing and Tian Wanjun, who collectively reduced approximately 130,000 shares, accounting for 0.107% of the company's total shares [1] - As of the latest report, Silk Road Vision has a market capitalization of 2.4 billion yuan [3] Group 2 - For the first half of 2025, Silk Road Vision's revenue composition shows that the CG business accounts for 99.98% of total revenue, while other businesses contribute only 0.02% [2]